ERAS Hisse Senedi Fiyat Grafiği
ERAS Finansal
Erasca Inc
$9.9
-48.3%
$-9.24
Kapanışta: Apr 28, 16:00:00 GMT-4
$10.09
1.91%
$0.18
Ön Piyasa: Apr 29, 05:31:16 GMT-4
Geri
Erasca Inc (ERAS) Finansal
Önemli İstatistikler
Önceki Kapanış
$19.15
Açılış fiyatı
$10.51
Günün Aralığı
$8.7 - $10.59
52 haftalık aralık
$1.06 - $18.2
İşlem hacmi
51.2M
Ort.Hacim
5.5M
Dividend yield
--
EPS (TTM)
-0.44
Piyasa Değeri
$3.1B
ERAS nedir?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
